Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon

References

• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• BagnisAPapadiaMScottoRTraversoCECurrent and emerging medical therapies in the treatment of glaucomaExpert Opin Emerg Drugs201116229330721406029
   PubMed Web of Science ®Google Scholar
• American Academy of OphthalmologyPreferred Practice Pattern^® Guidelines. Primary Open-Angle Glaucoma [homepage on the Internet]San Francisco, CAAmerican Academy of Ophthalmology (AAO) Glaucoma Panel2010 Available from: http://www.aaojournal.org/article/S0161-6420(15)01276-2/pdfAccessed January 29, 2016
   Google Scholar
• MarquisREWhitsonJTManagement of glaucoma: focus on pharmacological therapyDrugs Aging200522112115663346
   PubMed Web of Science ®Google Scholar
• McKinnonSJGoldbergLDPeeplesPWaltJGBramleyTJCurrent management of glaucoma and the need for complete therapyAm J Manag Care200814Suppl 1S20S2718284312
   PubMedGoogle Scholar
• StamperRLIntroduction and classification of the glaucomasStamperRLLiebermanMFDrakeMVBecker-Shaffer’s Diagnosis and Therapy of the Glaucomas8th edAmsterdam, the NetherlandsMosby Elsevier200917
   Google Scholar
• LouatiYShaarawyTControversy: is benzalkonium chloride necessary in antiglaucoma drops?J Curr Glaucoma Pract201263104107
   Google Scholar
• NoeckerRMillerKVBenzalkonium chloride in glaucoma medicationsOcul Surf20119315916221791190
   PubMed Web of Science ®Google Scholar
• BaudouinCLabbéALiangHPaulyABrignole-BaudouinFPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
   PubMed Web of Science ®Google Scholar
• TrocmeSHwangLJBeanGWSultanMBThe role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trialsAnn Pharmacother201044121914192121119099
   PubMed Web of Science ®Google Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma200817535035518703943
   PubMed Web of Science ®Google Scholar
• StewartWCStewartJANelsonLAOcular surface disease in patients with ocular hypertension and glaucomaCurr Eye Res201136539139821501071
   PubMed Web of Science ®Google Scholar
• de JongCStolwijkTKuppensEde KeizerRvan BestJTopical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucomaGraefes Arch Clin Exp Ophthalmol199423242212248034210
   PubMed Web of Science ®Google Scholar
• BronAVelasqueLRebicaHPouliquenPElenaPPRoulandJFComparaison du timolol sans conservateur et du timolol à délivrance prolongée donnés une fois par jour en association à du latanoprost. [Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost]J Fr Ophthalmol2004279 Pt 1971977 French
   Web of Science ®Google Scholar
• FrezzottiPFogagnoloPHakaGIn vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucomaActa Ophthalmol2014922e133e14024020826
   PubMed Web of Science ®Google Scholar
• ManniGCentofantiMOddoneFParravanoMBucciMGInterleukin-1β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockersAm J Ophthalmol20051391727715652830
   PubMed Web of Science ®Google Scholar
• MastropasquaLAgnifiliLFasanellaVConjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology studyActa Ophthalmol2013915e397e40523601909
   PubMed Web of Science ®Google Scholar
• RoulandJFTraversoCEStalmansIfor the T2345 Study GroupEfficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucomaBr J Opthalmol2013972196200
   PubMed Web of Science ®Google Scholar
• UusitaloHKaarnirantaKRopoAPharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteersActa Ophthalmol Suppl (Oxf)200824271318752509
   PubMedGoogle Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• BronAChiambarettaFPouliquenPRigalDRoulandJFIntérêt de la substitution d’un traitement journalier de 2 instillations de timolol par 1 instillation quotidienne de bêtabloquant non conservé chez des patients présentant un glaucome chronique ou une hypertonie oculaire [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]J Fr Ophtalmol2003267668674 French13130253
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyGanfort^® – Summary of Product Characteristics [homepage on the Internet]Irvine, CAAllergan, plc2006 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000668/WC500020625.pdfAccessed April 2, 2015
   Google Scholar
• BrandtJDCantorLBKatzLJBatoosinghALChouCBossowskaIfor the Ganfort Investigators Group IIBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma200817321121618414107
   PubMed Web of Science ®Google Scholar
• LewisRAGrossRLSallKNSchiffmanRMLiuCCBatoosinghALfor the Ganfort Investigators Group IIThe safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma201019642442619855289
   PubMed Web of Science ®Google Scholar
• GoldbergIGil PinaRLanzagorta-ArestiASchiffmanRMLiuCBejanianMBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trialBr J Ophthalmol201498792693124667994
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySummary of the European Public Assessment Report (EPAR) for Ganfort (Bimatoprost/Timolol) [homepage on the Internet]London, UKEMA Committee for Medicinal Products for Human Use (CHMP)2013 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000668/human_med_000804.jsp&mid=WC0b01ac058001d124Accessed April 1, 2015
   Google Scholar
• OkabeKKimuraHOkabeJEffect of benzalkonium chloride on transscleral drug deliveryInvest Ophthalmol Vis Sci200546270370815671302
   PubMed Web of Science ®Google Scholar
• DesbenoitNSchmitz-AfonsoIBaudouinCLocalisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometryAnal Bioanal Chem2013405124039404923430186
   PubMed Web of Science ®Google Scholar
• van der BijlPvan EykADMeyerDEffects of three penetration enhancers on transcorneal permeation of cyclosporineCornea200120550550811413407
   PubMed Web of Science ®Google Scholar
• PellinenPHuhtalaATolonenALokkilaJMäenpääJUusitaloHThe cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivoCurr Eye Res201237214515422049909
   PubMed Web of Science ®Google Scholar
• ShenJBejanianMSchiffmanRRemoval of preservative from Ganfort improves intraocular pressure (IOP) lowering in patients – a timolol dose-response phenomenonActa Ophthalmol (Copenh)201391s252 Abstract 4226. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2013.4226.x/abstractAccessed January 8, 2016
   Google Scholar
• KrupinTSingerPRPerlmutterJKolkerAEBeckerBOne-hour intraocular pressure response to timolol. Lack of correlation with long-term responseArch Ophthalmol19819958408417236087
   PubMedGoogle Scholar
• AlmAKoskelaTTaarnhøjJEffects of D-timolol and L-timolol eye drops on intraocular pressure and aqueous flow. A dose-response study in normal eyesActa Ophthalmol (Copenh)199068119222336928
   PubMed Web of Science ®Google Scholar
• BatchelorEDO’DayDMShandDGWoodAJInteraction of topical and oral timolol in glaucomaOphthalmology19798616065394062
   PubMed Web of Science ®Google Scholar
• CampbellSHHickey-DwyerMHardingSPDouble-masked three-period crossover investigation of timolol in control of raised intraocular pressureEye (Lond)1993711051088325398
   PubMed Web of Science ®Google Scholar
• DuBinerHBHillRKaufmanHTimolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucomaAm J Ophthalmol199612155225288610795
   PubMed Web of Science ®Google Scholar
• KatzIMHubbardWAGetsonAJGouldALIntraocular pressure decrease in normal volunteers following timolol ophthalmic solutionInvest Ophthalmol19761564894926402
   PubMedGoogle Scholar
• LaurenceJHolderDVogelRA double-masked, placebo-controlled evaluation of timolol in a gel vehicleJ Glaucoma19932317718219920515
   PubMedGoogle Scholar
• LetchingerSLFrohlichsteinDGlieserDKCan the concentration of timolol or the frequency of its administration be reduced?Ophthalmology19931008125912628341511
   PubMed Web of Science ®Google Scholar
• MillsKBBlind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucomaBr J Ophthalmol19836742162196338905
   PubMed Web of Science ®Google Scholar
• Mottow-LippaLSLippaEANaidoffMAClementiRBjornssonTJonesK008% timolol ophthalmic solution. A minimal-effect dose in a normal volunteer modelArch Ophthalmol1990108161642404487
   PubMedGoogle Scholar
• RowleySStauntonJEToschAStewart-JonesJHEdgarDFTurnerPA noninvasive tonometer in the measurement of the effects of pindolol and timolol on intraocular pressure in normal subjectsBr J Ophthalmol19816585365387295615
   PubMed Web of Science ®Google Scholar
• UusitaloRJPalkamaAStjernschantzJA study of the efficacy of two commercial preparations of timolol maleate with special reference to side effectsActa Ophthalmol (Copenh)19856366346413913273
   PubMed Web of Science ®Google Scholar
• ZimmermanTJKassMAYablonskiMEBeckerBTimolol maleate: efficacy and safetyArch Ophthalmol1979974656658371597
   PubMedGoogle Scholar
• ZimmermanTJKaufmanHETimolol: a β-adrenergic blocking agent for the treatment of glaucomaArch Ophthalmol1977954601604322648
   PubMedGoogle Scholar
• ZimmermanTJKaufmanHETimolol: dose response and duration of actionArch Ophthalmol1977954605607322649
   PubMedGoogle Scholar
• YamamotoTKitazawaYAzumaITsukaharaSNakashimaMfor the WP-934 Study GroupClinical evaluation of a new formula of timolol maleate (WP-934 ophthalmic solution)Jpn J Opthalmol1997414244250
   Web of Science ®Google Scholar
• OlatejuSOAjayiAAThe lack of efficacy of topical beta-blockers, timolol and betaxolol on intraocular pressure in Nigerian healthy volunteersEye (Lond)199913Pt 675876310707140
   PubMed Web of Science ®Google Scholar
• Le JeunneCLHuguesFCDufierJLMuneraYBringerLBronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranololJ Clin Pharmacol1989292971012565918
   PubMed Web of Science ®Google Scholar
• LeierCVBakerNDWeberPACardiovascular effects of ophthalmic timololAnn Intern Med198610421971993946944
   PubMed Web of Science ®Google Scholar
• NelsonWLFraunfelderFTSillsJMArrowsmithJBKuritskyJNAdverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985Am J Ophthalmol198610256066113777080
   PubMed Web of Science ®Google Scholar
• NetlandPAWeissHSStewartWCCohenJSNussbaumLLfor the Night Study GroupCardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucomaAm J Opthalmol19971234465477
   PubMed Web of Science ®Google Scholar
• StewartWCStewartJAJacksonALCardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapyActa Ophthalmol Scand200280327728112059866
   PubMedGoogle Scholar
• UmetsukiMHKotegawaTNakamuraKNakanoSNakatsukaKTemporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy menJ Clin Pharmacol199737158639048274
   PubMed Web of Science ®Google Scholar
• SicaDAPharmacotherapy in congestive heart failure: cardiopulmonary effects of ophthalmically administered beta-blockersCongest Heart Fail199952818512189325
   PubMedGoogle Scholar
• ZimmermanTJCanalePTimolol – further observationsOphthalmology1979861166169530562
   PubMed Web of Science ®Google Scholar
• KosmanMETimolol in the treatment of open angle glaucomaJAMA19792412123012303439303
   PubMed Web of Science ®Google Scholar
• RosFEDakeCLTimolol eye drops: bradycardia or tachycardia?Doc Ophthalmol19804822832897398530
   PubMed Web of Science ®Google Scholar
• CherITransfer to timolol: selective use of a new mode of therapyAust J Ophthalmol1980821651727447802
   PubMedGoogle Scholar
• SteinertRFThomasJVBogerWP3rdLong-term drift and continued efficacy after multiyear timolol therapyArch Ophthalmol19819911001037006575
   PubMedGoogle Scholar
• BogerWP3rdShortterm “escape” and longterm “drift.” The dissipation effects of the beta adrenergic blocking agentsSurv Ophthalmol198328Suppl2352426141645
   PubMedGoogle Scholar
• MaclureGMChronic open angle glaucoma treated with Timolol. A four year studyTrans Ophthalmol Soc U K1983103Pt 178836581640
   PubMedGoogle Scholar
• GandolfiSARestoring sensitivity to timolol after long-term drift in primary open-angle glaucomaInvest Ophthalmol Vis Sci19903123543582406218
   PubMed Web of Science ®Google Scholar
• GandolfiSAVecchiMSerial administration of adrenergic antagonist and agonist (“pulsatile therapy”) reduces the incidence of long-term drift to timolol in humansInvest Ophthalmol Vis Sci19963746846888595970
   PubMed Web of Science ®Google Scholar
• NeufeldAHZawistowskiKAPageEDBrombergBBInfluences on the density of beta-adrenergic receptors in the cornea and iris – ciliary body of the rabbitInvest Ophthalmol Vis Sci1978171110691075212382
   PubMed Web of Science ®Google Scholar
• KahleGKaulenPSchererVWollensakJZunahme der beta-adrenergen rezeptoren in kaninchen in langfristige lokale verabreichung von betablockern. [Increase in beta-adrenergic receptors in rabbits in long-term local administration of beta-blockers]Ophthalmologe1993906626630 German7907242
   PubMedGoogle Scholar
• WoodwardDFPhelpsRLKraussAHBimatoprost: a novel antiglaucoma agentCardiovasc Drug Rev200422210312015179448
   PubMed Web of Science ®Google Scholar
• HeelRCBrogdenRNSpeightTMAveryGSTimolol: a review of its therapeutic efficacy in the topical treatment of glaucomaDrugs19791713855369807
   PubMed Web of Science ®Google Scholar